Influence of Ovarian Stimulation With 200 IU of hCG, (Administered in the Late Follicular Phase Among ICSI Patients Undergoing a GnRH-antagonist Protocol), on the Endometrium on the Day of Oocyte Pick-up
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- number of oocytes
研究概览
简要总结
The purpose of the present study is to assess the influence of the administration of low dose hCG on the endometrium. The study is a randomised trial where 2 groups of patients, undergoing a gonadotropin-releasing hormone antagonist protocol for in vitro fertilization, are studied. In addition to the histological findings, by analysing the correlation of the morphological pattern and gene expression profile of human endometrium on the day of oocyte retrieval in patients of both treatment groups, the investigators want to study the implantation potential.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Investigator)
入排标准
- 年龄范围
- 18 Years 至 36 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •< 36 years on day of randomisation
- •FSH < 12 in the early follicular phase
- •Normal ultrasound scan
- •BMI between 18 and 29 (both inclusive)
- •Randomisation at outpatient clinic
排除标准
- •Endometriosis ≥ grade 3
- •PCO syndrome
- •Poor responder
- •Endocrine or metabolic abnormalities
研究组 & 干预措施
Recombinant FSH
Patients undergo a standard antagonist protocol for in-vitro fertilisation, and are stimulated with recombinant gonadotropins. Histology and gene expression is studied on the endometrium.
干预措施: human menopausal gonadotropin (Drug)
human chorionic gonadotropin
Patients undergo an antagonist protocol for in-vitro fertilisation and are stimulated with recombinant gonadotropins. When the patient has an estradiol value of 600 ng/L or more and when the patient has at least 6 follicles of 12 mm, the administration of gonadotropins is stopped and replaced by low dose human chorionic gonadotropins.
Histology and gene expression is studied on the endometrium
干预措施: human menopausal gonadotropin (Drug)
结局指标
主要结局
number of oocytes
时间窗: 2 weeks after start of the treatment
次要结局
未报告次要终点